Evidence map›Paper›PMID 42230485›Full record

ArticleHormones (Athens, Greece)2026

Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men.

Amna Naveed, Margaret F Lippincott, Maria Stamou, Ravi Balasubramanian, Nora K Bryant, Stephanie B Seminara

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01438073 (Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01438073 phase1completednot on this map

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

TypeinterventionalSponsorMassachusetts General HospitalRan2011 to 2016Enrolled96ConditionsHypogonadotropic Hypogonadism, Healthy Postmenopausal Women, AgonadismArmskisspeptin 112-121, GnRH
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amna NaveedReproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.ORCID http://orcid.org/0009-0001-1309-5534
Margaret F LippincottReproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.
Maria StamouReproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.
Ravi BalasubramanianReproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.
Nora K BryantReproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.
Stephanie B SeminaraReproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA. sseminara@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-0445-3029

Funding

The Harvard Clinical and Translational Science CenterUL1TR002541 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2018 to 2022
$93.0M
The Massachusetts General Hospital Harvard Center for Reproductive MedicineP50HD104224 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI TALKOWSKI, MICHAEL E · 2021 to 2025
$7.8M
Towards Curative Therapies for Hypogonadotropic DiseasesR37HD043341 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI Stephanie Beth Seminara · 2020 to 2026
$5.8M
Elucidating the Role of the FGFR1 Signaling Pathway in the Intersection of Reproduction and MetabolismK23HD117006 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI Maria Stamou · 2025 to 2026
$341k
Eunice Kennedy Shriver National Institute of Child Health and Human Development R37HD043341FDA HHS R01 FD007843National Center for Translational Research in Reproduction and Infertility P50HD104224NCATS NIH HHS UL1 TR002541NICHD NIH HHS K23 HD117006NICHD NIH HHS P50 HD104224NICHD NIH HHS R37 HD043341U.S. Food and Drug Administration R01FD007843
6 · The paper itself

Abstract

purposeKisspeptin stimulates gonadotropin-releasing hormone (GnRH) release and, by extension, gonadotropin secretion. Although continuous kisspeptin administration has been shown to dampen kisspeptin-induced GnRH release in non-human primates [1, 2], this has not been replicated in the limited human studies reported to date. The objective of this study was to examine the effects of continuous kisspeptin administration on luteinizing hormone (LH) secretion in healthy men.

methodsThree healthy adult men received a continuous intravenous infusion of kisspeptin-10 at a dose of 12.5 mcg/kg/h for 24 h and underwent frequent blood sampling to characterize the effect on reproductive hormones.

resultsContinuous administration of kisspeptin resulted in an immediate increase in LH concentrations, from a baseline of 2.8-3.8 mIU/mL to the highest values of 17.5-30.6 mIU/mL (5- to eightfold above baseline), reached within 12-20 h of infusion onset. LH concentrations subsequently declined by 13-47% from max to end of the infusion, settling at 10.7-22.8 mIU/mL. FSH and testosterone rose modestly in parallel.

conclusionWhile kisspeptin boluses have been employed to probe GnRH pulse generation, continuous infusion of kisspeptin is a complementary physiologic tool used to study dynamic changes in GnRH-induced LH secretion. Further studies are warranted to further elucidate the physiologic response of the kisspeptin receptor to non-pulsatile ligand administration. CLINICAL

trial registrationNCT01438073 (August 24, 2011).

Indexed as

Continuous infusionDesensitizationKisspeptinLuteinizing hormone

Identifiers

PMID42230485
PMCPMC13386888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.